New mRNA vaccine aims to shield against RSV
NCT ID NCT06287450
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new mRNA vaccine called IN006 to see if it is safe and helps the body fight RSV, a virus that can cause serious breathing problems. About 200 healthy adults, both younger (18-59) and older (60-79), will receive one or two shots of the vaccine or a placebo. Researchers will monitor side effects and measure the immune response over 12 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nasal spray vaccine aims to shield children from RSV
- Inhaled interferon could be new weapon against severe RSV in young children
- New oral pill aims to fight RSV in adults
- New antiviral pill aims to shorten RSV symptoms in vulnerable adults
- New rapid test could spot flu and RSV in minutes at your local clinic
- Experimental 'Storm Stopper' therapy tested for COVID-19, flu, and RSV